SB has been approved by the FDA for pediatric use children 9yrs up BOTOX on the other hand isn't.
BOTOX website has this warning:
"The safety and effectiveness of BOTOX® for hyperhidrosis in other body areas have not been established. Weakness of hand muscles and blepharoptosis may occur in patients who receive BOTOX® for palmar hyperhidrosis and facial hyperhidrosis, respectively. Patients should be evaluated for potential causes of secondary hyperhidrosis (eg, hyperthyroidism) to avoid symptomatic treatment of hyperhidrosis without the diagnosis and/or treatment of the underlying disease.Safety and effectiveness of BOTOX® have not been established for the treatment of axillary hyperhidrosis in pediatric patients under age 18."
Interesting some use BOTOX on hands and face to treat hyperhidrosis we know BOT investigating application of SB on hands and feet some future news on this I expect.
- Forums
- ASX - By Stock
- BOT - Anything but charting
SB has been approved by the FDA for pediatric use children 9yrs...
-
-
- There are more pages in this discussion • 1,844 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $671.1M |
Open | High | Low | Value | Volume |
37.0¢ | 37.5¢ | 37.0¢ | $151.3K | 406.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 219857 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 194851 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 130837 | 0.370 |
10 | 99517 | 0.365 |
16 | 271384 | 0.360 |
7 | 220353 | 0.355 |
26 | 1051912 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 44778 | 1 |
0.385 | 245000 | 3 |
0.390 | 10960 | 1 |
0.395 | 123443 | 3 |
0.400 | 179748 | 4 |
Last trade - 10.30am 07/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
BOT (ASX) Chart |